RA Capital Management announces close of $1.4 billion acquisition of Aliada Therapeutics by AbbVie
- AbbVie has completed a $1.4 billion acquisition of Aliada Therapeutics, a company from RA Capital's Raven incubator.
- Aliada's lead asset, ALIA-1758, is an anti-pyroglutamate amyloid beta antibody in Phase 1 trials for Alzheimer's disease.
- ALIA-1758 features a novel technology for crossing the blood-brain barrier, enhancing drug delivery to the central nervous system.
- The acquisition marks the second significant purchase of a Raven-grown company in 2024, following Novartis' acquisition of Mariana Oncology.
Read more
Corcept announces results from phase 2 study of dazucorilant in patients with amyotrophic lateral sclerosis (ALS)
- The DAZALS study was a randomized, double-blind, placebo-controlled Phase 2 trial evaluating dazucorilant in ALS patients.
- The trial did not meet its primary endpoint of improving ALS Functional Rating Scale-Revised (ALSFRS-R) scores.
- No deaths were observed in the 300 mg dazucorilant group, while 5 deaths occurred in the placebo group (p-value: 0.02).
- An open-label, long-term extension study will continue, with overall survival assessed in March 2025.
Read more
Neuraxpharm and Pharmathen enter into strategic co-development agreement to develop long-acting injectable therapies
- Neuraxpharm and Pharmathen have formed a strategic alliance to co-develop long-acting injectable therapies for CNS disorders.
- Neuraxpharm will commercialize these therapies in Europe and other regions where it has a presence, while Pharmathen will cover North America and other areas.
- Pharmathen's LATT program aims to convert short-acting dosage forms into long-acting injectables, enhancing patient compliance and convenience.
- Pharmathen will handle technology, manufacturing, and supply, while Neuraxpharm will focus on registration and marketing in Europe.
Read more
Enlivex receives regulatory authorization for phase I trial of Allocetra in TMJ osteoarthritis
- Enlivex Therapeutics has received approval from the Israeli Ministry of Health to start a Phase I trial for Allocetra in TMJ osteoarthritis.
- The trial will be conducted at Sheba Medical Center, involving six patients with insufficient response to conventional treatments.
- Primary endpoints include safety and tolerability, while efficacy will be assessed through changes in TMJ pain and joint functionality over 12 months.
- Allocetra aims to reprogram macrophages to their homeostatic state, potentially offering a new treatment for TMJ osteoarthritis.
Read more
